AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.05

+1.7%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$898.69M
EPS-1.7400
P/E Ratio-5.20
Earnings Date08/12/2026

spry

Research Development Expenses

Last Annual Value

13.18M

3-Year CAGR

-10%

5-Year CAGR

-1%

10-Year CAGR

-1%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of research-development-expenses

SPRY · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
13.18M
-13.4%-8.3%N/A 
25.24M
-30.0%-17.4%-8.5%
SVRA logo
Savara Inc.
NASDAQ:SVRA
81.40M
22.5%22.9%25.8%
251.07M
29.6%24.3%28.5%
22.84M
37.5%-18.7%N/A
18.67M
-32.0%-13.2%N/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
114.12M
2.3%19.8%N/A
102.93M
18.1%37.9%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
61.53M
12.0%32.6%20.6%
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.05, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.05